Anemia observed after upadacitinib treatment (selective JAK1 inhibitor) may suggest that this drug also inhibits JAK2, particularly when used in high dosage (IC50 = 0.043 μM for JAK1 vs. IC50 = 0.2 μM for JAK2) [29,105]. Here, JAK1 is linked to anemia.